[{"orgOrder":0,"company":"Vaxess","sponsor":"National Science Foundation","pharmaFlowCategory":"D","amount":"$2.0 million","upfrontCash":"Undisclosed","newsHeadline":"Vaxess Technologies Awarded NSF and DARPA Funding for Development of mRNA-Based Single-Dose, Refrigeration-Free Vaccine Patch","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed"},{"orgOrder":0,"company":"Vaxess","sponsor":"GC Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vaxess Announces Production of The First GMP Batch of MIMIX\u2122 Technology Vaccine Patches for an Upcoming Phase 1 Seasonal Influenza Clinical Trial; Clinical Entry Expected This Summer Based on a Successful February Pre-CTA Meeting With Health Canada","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling"},{"orgOrder":0,"company":"Vaxess","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vaxess Announces Interim Results from Phase I Clinical Trial of MIMIX-Flu Vaccine Patch","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I"}]
Find Clinical Drug Pipeline Developments & Deals by Vaxess
VX-103 (MIMIX-flu vaccine ) were well tolerated, with no serious or severe adverse events. The overall rate of reported systemic events was favorable as compared to traditional vaccines delivered by needle and syringe.
Funding will be used to integrate mRNA-based vaccines and gene modulators provided through a collaboration with the Santangelo Lab at Georgia Tech into MIMIX patches to improve the efficacy and administration of novel mRNA-based vaccines and other medical countermeasures.